TrialJournal of clinical pharmacology2014

A FIM study to assess safety and exposure of inhaled single doses of AP301-A specific ENaC channel activator for the treatment of acute lung injury.

Richard Schwameis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.